Evidence map›Paper›PMID 31265254›Full record

ArticleBioconjugate chemistry2019

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection.

Jennifer A Fulcher, Kyle Tamshen, Alexander L Wollenberg, Valerie A Kickhoefer, Jan Mrazek, Julie Elliott, F Javier Ibarrondo, Peter A Anton, Leonard H Rome, Heather D Maynard and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jennifer A FulcherDivision of Infectious Diseases, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
Kyle TamshenDepartment of Chemistry and Biochemistry , University of California , Los Angeles , California , United States.
Alexander L WollenbergDepartment of Chemistry and Biochemistry , University of California , Los Angeles , California , United States.
Valerie A KickhoeferDepartment of Biological Chemistry , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
Jan MrazekDivision of Infectious Diseases, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
Julie ElliottVatche and Tamar Manoukian Division of Digestive Diseases , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
F Javier IbarrondoDivision of Infectious Diseases, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
Peter A AntonVatche and Tamar Manoukian Division of Digestive Diseases , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
Leonard H RomeDepartment of Biological Chemistry , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.
Heather D MaynardDepartment of Chemistry and Biochemistry , University of California , Los Angeles , California , United States.ORCID 0000-0003-3692-6289
Timothy DemingDepartment of Chemistry and Biochemistry , University of California , Los Angeles , California , United States.ORCID 0000-0002-0594-5025
Otto O YangDivision of Infectious Diseases, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , California , United States.ORCID 0000-0003-1970-8992
University of California, Los Angeles · USCalifornia NanoSystems Institute · USAIDS Healthcare Foundation · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Topical Microbicides: Targeted Intracellular DeliveryR01AI112016 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A, YANG, OTTO O · 2014 to 2017
$2.3M
NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI112016
6 · The paper itself

Abstract

"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood mononuclear cells (PBMC), predominately dendritic cells, monocytes/macrophages, and activated T cells. As these cell types are the primary targets for human immunodeficiency virus type 1 (HIV-1) infection, we examined the utility of recombinant human vaults for targeted delivery of antiretroviral drugs. We chemically modified three different antiretroviral drugs, zidovudine, tenofovir, and elvitegravir, for direct conjugation to vaults. Tested in infection assays, drug-conjugated vaults inhibited HIV-1 infection of PBMC with equivalent activity to free drugs, indicating vault delivery and drug release in the cytoplasm of HIV-1-susceptible cells. The ability to deliver functional drugs via vault nanoparticle conjugates suggests their potential utility for targeted drug delivery against HIV-1.

Indexed as

Anti-Retroviral AgentsCells, CulturedCytoplasmDrug Delivery SystemsDrug LiberationHIV-1HIV InfectionsHumansLeukocytes, MononuclearNanoparticlesRibonucleoproteinsAnti-Retroviral AgentsRibonucleoproteins

Identifiers

PMID31265254
PMCPMC7434464
OpenAlexW2954639921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.